SCHEMBL6790433

SCHEMBL6790433

C/C(=C/C(=O)Nc1ccc(NC(=O)Nc2ccc(Oc3ccccc3)cc2)cc1C(=O)O)c1ccc2ccccc2c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.66
NR1H4 Q96RI1 1/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
SERPINE1 P05121 1/20 0.45
MAPT P10636 2/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
DEGS1 O15121 1/20 0.43
GRIK1 P39086 1/20 0.43
GRIK2 Q13002 1/20 0.43
HDAC3 O15379 1/20 0.43
BRAF P15056 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6786594 0.93 TERT (0.72) TERTKMT2AMEN1MAPTNPC1
SCHEMBL6786590 0.90 TERT (0.55) TERTNR1H4KMT2AMEN1MAPT
SCHEMBL6786810 0.88 TERT (0.71) TERTKMT2AMAPTNPC1RAB9A
SCHEMBL6781944 0.87 TERT (0.75) TERTKMT2AMEN1MAPTNPC1
SCHEMBL6783902 0.84 TERT (0.62) TERTKMT2AMEN1MAPTNPC1
SCHEMBL6783765 0.84 TERT (0.59) TERTKMT2AMEN1MAPTNPC1
SCHEMBL6787182 0.83 TERT (0.66) TERTNR1H4MAPTDEGS1
SCHEMBL6784699 0.83 TERT (0.75) TERTKMT2AMEN1MAPTNPC1
SCHEMBL4024783 0.81 TERT (0.80) TERTKMT2AMEN1MAPTRAB9A
SCHEMBL6785193 0.81 TERT (0.69) TERTKMT2AMEN1DEGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885NR1H4 3652/4885KMT2A 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.